Convolutional neural network accurately identifies “mass effect” lesions in more than 50 disease entities.
An artificial intelligence model based on MRI images can accurately identify which brain lesions cause mass effect and which do not for a wide variety of brain diseases, according to findings presented at SIIM2020.
Brain lesions have a number of diagnostically and prognostically relevant features – a key one being whether it exerts a “mass effect” – a distortion or compression of ventricles and sulci. To make this determination, investigators from the University of Pennsylvania, University of California San Francisco, and University of Texas Austin developed a convolutional neural network (CNN) that can be used across many underlying pathologies.
To create the CNN and achieve a high level of accuracy, they extracted T1 and T2-FLAIR images from 384 MRI studies (298 negative, 88 positive) of patients who had 60 different disease entities. Of those images 189 were used for training, 54 for validation, and 142 for a held-out test, ensuring that two-to-three samples were in the test set. In addition, they extracted cerebral spinal fluid masks from the T1 images, and the brain was extracted from the FLAIR image.
Related Content: MRI Distinguishes Brain Lesions
Overall, researchers determined their mass effect detection model was 84.5 percent accurate. The network, they said, performed well across 53 disease entities.
As next steps, the team plans to: classify negative mass effect, use multiple channels to improve tissue segmentation, and produce saliency maps to determine why the classifier is making its decisions.
For more coverage of SIIM2020, click here.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.